Catheter-related thrombosis

Journal of Intravenous Nursing

Volumn 24, Issue 3 SUPPL., 2001, Pages

  Mayo, Donna Jo ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; RETEPLASE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ADULT; ARTICLE; BLOOD CLOTTING; CASE REPORT; CATHETER; CLINICAL FEATURE; FEMALE; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; HEALTH CARE PERSONNEL; HEMOSTASIS; HUMAN; LUNG EMBOLISM; PATHOPHYSIOLOGY; SUBCLAVIAN VEIN; SUPERIOR CAVA VEIN OBSTRUCTION; THROMBOGENESIS; THROMBOSIS; VASCULAR ACCESS; VEIN THROMBOSIS;

EID: 0035009190     PISSN: 08965846     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Haire WB, Herbst SF. Consensus conference on the use of alteplase (t-PA) for the management of thrombotic catheter dysfunction. Journal of Vascular Access Devices. 2000;5(2):28-36.
2. Bagnall-Reeb H. Diagnosis of central venous access device occlusion, J Intraven Nurs. 1998;21(5S):116-121.
3. Andris DA, Krzywda EA. Catheter pinch-off syndrome: recognition and management. J Intraven Nurs. 1997;20:233-237.
4. Herbst S, Kline L, McKinnon B. Vascular access devices: managing occlusions and related complications in home infusion. Infusion. 1998;4(8 suppl):1-32.
5. Hadaway LC. Major thrombotic and nonthrombotic complications. J Intraven Nurs. 1998;21(5S):143-160.
6. Deithorn ML, Weld LM. Physiologic mechanisms of hemostasis and fibrinolysis. J Cardiovasc Nurs. 1989;4(1):1-10.
7. Gram J. The haemostatic balance in groups of thrombosis-prone patients. Dan Med Bull. 1990;37(3):210-234.
8. Comp P. Overview of the hypercoagulable state. Semin Thromb Hemost. 1990;16(2):158-161.
9. Vine DL. Coronary thrombolysis and aging. Kans Med. 1990;1(2):47-48.
10. Kline EM. Pharmacologic review of thrombolytic agents. Critical Care Nursing Clinics of North America. 1990;2(4):613-627.
11. Haire WB, Atkinson JB, Stephens LC, Kotulak GD. Urokinase versus recombinant tissue plasminogen activator in thrombosed central venous catheters: a double-blind, randomized trial. Thromb Haemost. 1994;72(4):543-547.
12. Calis KA, Cullinane AM, Home MK. Bioactivity of cryopreserved alteplase solutions. Am J Health Syst Pharm. 1999;56:2056-2057.
13. Kohnert U, Rudolph R, Verheijen JH. Biochemical properties of the kringle 2 and protease domains are maintained in the refolded deletion varient BM 06.022. Protein Eng. 1992;5:93-100.
14. Horne MK, Mayo DJ. Low-dose urokinase infusions to treat fibrinous obstruction of venous access devices in cancer patients. J Clin Oncol. 1997;15(7):2709-2714.
15. Peterson J, Delaney JH, Brakstad MT, Rowbotham R, Bafley CM. Silicone venous access devices positioned with their tips high in the superior vena cava are more likely to malfunction. Am J Surg. 1999;178(7):38-41.
16. Kearns PJ, Coleman S, Wehner JH. Complications of long arm-catheters: a randomized trial of central vs peripheral tip location. Journal of Parenteral and Enteral Nutrition. 1996;20(1):20-24.
17. Corso F, Wolfe BM. Complications in vascular access devices. Nutrition in Clinical Practice. 1993;8(4):143-144.
18. Dierks MM, Whitman ED. Catheter tip position in the analysis on central venous access device outcome. Journal of Vascular Access Devices. 1995;1(3):11-14.
19. Jobe MI. Mechanisms of coagulation and fibrinolysis. In: Stiene-Martin EA, Lotspeich-Steininger CA, Kopke JA, eds. Clinical Hematology: Principle, Procedures, Correlations. Philadelphia, PA: Lippincott; 1998:612-634.
20. Mayo DJ. Current treatment options for catheter-related thrombosis. Journal of Vascular Access Devices. 2000;5(2):10-20.
21. Motin J, Fischer G, Evreaux J, Interét da la voie sous-claviculaire en reanimation prolongee. Lyon Med. 1964;212:583-593.
22. Hoshal VL, Ause RG, Hoskins PA. Fibrin sleeve formation on indwelling subclavian central venous catheters. Arch Surg. 1971;102(4):253-258.
23. Brismar B, Haedstedt C, Jacobson S. Diagnosis of thrombosis by catheter phlebography after prolonged central venous catheterization. Ann Surg. 1981;194(6):779-783.
24. DeCicco M, Matovic M, Balestren L, et al. Central venous thrombosis: an early and frequent complication in cancer patients bearing long-term silastic catheter: a prospective study. Thromb Res. 1997;86(2):101-113.
25. Mayo DJ. Administering urokinase for catheter clearance. Nursing98. 1998;28(12):50-52.
26. Mayo DJ. Fibrin sheath formation and chemotherapy extravasation: a case report. Support Care Cancer. 1998;6:51-56.
27. Tolar B, Gould JR. The timing and sequence of multiple device-related complications in patients with long term indwelling Groshong catheters. Cancer. 1996;78(6):1308-1313.
28. Monreal M, Alastrue A, Rull M, Mira X, Rasell R, Abad A. Upper extremity deep venous thrombosis in cancer patients with venous access devices: prophylaxis with low molecular weight heparin (Fragmin). Thromb Haemost. 1996;75(2):252-252.
29. Home MK, Mayo DJ, Alexander HR, et al. Venographic surveillance of tunneled venous access devices in adult oncology patients. Ann Surg Oncol. 1995;2(2):174-178.
30. Orr ME, Ryder MA. Vascular access devices: perspectives on designs, complications, and management. Nutrition in Clinical Practice. 1993;8(4):145-152.
31. Steed DL, Teodori MF, Peitzman AB, McAuley CE, Kapoor WN, Webster MW. Streptokinase in the treatment of subclavian vein thrombosis. Journal of Vascular Surgery. 1986;4(1):28-32.
32. Seigal EL, Jew AC, Delcore R, Iliopoulos JI, Thomas JH. Thrombolytic therapy for catheter-related thrombosis. Am J Surg. 1993;166:716-719.
33. Fraschini G, Jadeja J, Lawson M, Holmes FA, Carrasco HC, Wallace S. Local infusion of urokinase for the lysis of thrombosis associated with permanent central venous catheters in cancer patients. J Clin Oncol. 1987;5(4):672-678.
34. Druy EM, Trout HH, Giordano JM, Hix WR. Lytic therapy in the treatment of axillary and subclavian vein thrombosis. Journal of Vascular Surgery. 1985;2(6):821-827.
35. Chang R, Home MK, Mayo DJ, Doppman JL. Pulse-spray treatment of subclavian and jugular venous thrombi with recombinant tissue plasminogen activator. Journal of Vascular and Intervention Radiology. 1996;7:845-851.
36. Mayo DJ, Pearson DC, Home MK. Superior vena cava thrombosis associated with a central venous access device: a case report. Clinical Journal of Oncology Nursing. 1997;1(1):5-10.
37. Stewart IE. Superior vena cava syndrome: an oncologic complication. Semin Oncol Nurs. 1996;12(4):312-317.
38. Rusher AH, Tidwell K, Scroggin C, Bodeker L. Treatment of catheter induced obstruction of the superior vena cava with Wallstent endoprosthesis. J Ark Med Soc. 1997;94(7):299-300.
39. Hsu J, Chiang C, Hsu W, Hsu J, Chiang C. Superior vena cava syndrome in lung cancer: an analysis of 54 cases. Kaohsiung Journal of Medical Sciences. 1995;11:568-573.
40. Kee ST, Kinoshita L, Razavi MK, Nyman UR, Semba CP, Dake MD. Superior vena cava syndrome: treatment with catheter-directed thrombolysis and endovascular stent placement. Radiology. 1998;206:187-193.
41. Monreal M, Raventos A, Lerma R. Pulmonary embolism in patients with upper extremity DVT associated to venous central lines - a prospective study. Thromb Haemost. 1994;72(4):548-550.
42. Haire WB, Lieberman RP. Thrombosed central venous catheters: restoring function with a 6-hour urokinase infusion after failure of a bolus of urokinase. Journal of Parenteral and Enteral Nutrition. 1992;16:129-132.
43. Esteridge BJ, Lefar AT. Complications of indwelling venous access devices in cancer patients. J Clin Oncol. 1995;13(1):233-238.
44. Richardson D. Tracking catheters: the care continuum. J Intraven Nurs. 2000;23(1);35-43.